Survival and Biomarker Analyses From the OpACIN Immunotherapy Trials in Stage III Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Survival and Biomarker Analyses From the OpACIN-neo and OpACIN Neoadjuvant Immunotherapy Trials in Stage III Melanoma
Nat. Med. 2021 Feb 01;27(2)256-263, EA Rozeman, EP Hoefsmit, ILM Reijers, RPM Saw, JM Versluis, O Krijgsman, P Dimitriadis, K Sikorska, BA van de Wiel, H Eriksson, M Gonzalez, A Torres Acosta, LG Grijpink-Ongering, K Shannon, JBAG Haanen, J Stretch, S Ch'ng, OE Nieweg, HA Mallo, S Adriaansz, RM Kerkhoven, S Cornelissen, A Broeks, WMC Klop, CL Zuur, WJ van Houdt, DS Peeper, AJ Spillane, ACJ van Akkooi, RA Scolyer, TNM Schumacher, AM Menzies, GV Long, CU BlankFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.